Shared on 05 Nov 25
Fair value Increased 11%Analysts have raised their fair value price target for Aurinia Pharmaceuticals from $11.71 to $13.00. They cite stronger-than-expected Lupkynis sales and improved profit margins as key factors supporting this upward revision.
Shared on 01 Aug 25
Fair value Increased 17%Pipeline Progress And ACR Updates Will Shape Future Opportunities
The consensus analyst price target for Aurinia Pharmaceuticals has increased to $11.57, reflecting heightened investor optimism as evidenced by a higher future P/E ratio, despite a modest decline in net profit margin. What's in the News Aurinia Pharmaceuticals raised its 2025 total revenue guidance to $260–$270 million and net product sales guidance to $250–$260 million.